RAB11 family interacting protein 5Genealiases: GAF1 · RIP11 · gaf-1 · pp75 · rab11-FIP5
Q-omics provides the consensus-scored RAB11FIP5 profile across patient tissues and cancer cell-line models. RAB11FIP5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RAB11FIP5 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, RAB11FIP5 protein abundance shows 33,774 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where RAB11FIP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB11FIP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB11FIP5 survival associations across molecular data types. RAB11FIP5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB11FIP5 RNA expression–survival associations across cancer types. High RAB11FIP5 expression shows unfavorable associations in MESO, ACC, LIHC, BLCA and OV, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RAB11FIP5 RNA expression.
This table summarizes RAB11FIP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB11FIP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB11FIP5 shows lower tumor expression in KICH, UCEC and KIRP and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher RAB11FIP5 RNA expression in tumor versus normal tissue (log2 FC = +1.465, t-test p < 0.001).
This table shows molecular features associated with RAB11FIP5 in patient tissues and cancer cell lines. In patient samples, RAB11FIP5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB11FIP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
